AstraZeneca Balance Sheet Health
Financial Health criteria checks 3/6
AstraZeneca has a total shareholder equity of $37.5B and total debt of $33.5B, which brings its debt-to-equity ratio to 89.2%. Its total assets and total liabilities are $102.3B and $64.8B respectively. AstraZeneca's EBIT is $11.2B making its interest coverage ratio 12. It has cash and short-term investments of $8.0B.
Key information
89.2%
Debt to equity ratio
US$33.45b
Debt
Interest coverage ratio | 12x |
Cash | US$8.02b |
Equity | US$37.50b |
Total liabilities | US$64.79b |
Total assets | US$102.29b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: AZN's short term assets ($25.6B) do not cover its short term liabilities ($28.9B).
Long Term Liabilities: AZN's short term assets ($25.6B) do not cover its long term liabilities ($35.9B).
Debt to Equity History and Analysis
Debt Level: AZN's net debt to equity ratio (67.8%) is considered high.
Reducing Debt: AZN's debt to equity ratio has reduced from 189.1% to 89.2% over the past 5 years.
Debt Coverage: AZN's debt is well covered by operating cash flow (29%).
Interest Coverage: AZN's interest payments on its debt are well covered by EBIT (12x coverage).